PMBL can be distinguished from DLBCL by its characteristic immunophenotype, including expression of MAL, CD200, PDL1, PDL2 [24–26], molecular findings of CIITA abnormalities, and PDL1/PDL2 gains [27]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.